09/21 Taiwan BIO Weekly
2026-09-21 |
| Taiwan BIO Weekly |
| Tanvex BioPharma's Bora Biologics to Supply Recombinant Protein to Australia's Q-Sera 18 September, 2026 nvex BioPharma (TW: 6541) announced on the 17th of September that its subsidiary Bora Biologics has signed a long-term supply agreement with Australian blood collection technology company Q-Sera to supply recombinant RAPClot protein for VenoJect II RAPClot vacuum blood collection tubes, which are in turn being supplied to Japan's Terumo. Bora Biologics has worked with Q-Sera since 2021, leveraging its proprietary cell-line and recombinant protein manufacturing capabilities to successfully scale RAPClot production to commercial scale. More... (in Chinese) |
| TTY Biopharm's Three Growth Engines Ready to Fire as New Freeze-Drying Line Starts Q4, Doubling Capacity 17 September, 2026 TTY Biopharm (TW: 4105) General Manager Hou Ching-Lan said at an investor conference that first-half revenue, operating profit, and earnings per share all hit record highs for the period, with revenue through August up 8% year-over-year. More... |
| Sinphar Pharmaceutical Partners with Japanese Pharma to Expand in Southeast Asia 17 September, 2026 Sinphar Pharmaceutical (TW: 1734) is expanding its pharmaceuticals, functional foods, and medical aesthetics and skincare businesses through new product launches, market expansion, and increased investment. Next year, the company plans to launch four pharmaceutical, five functional food, and nine cosmetics products. It is also partnering with a major Japanese pharmaceutical company on R&D and manufacturing for ASEAN markets, while expanding Japanese product distribution in Taiwan and contract manufacturing for cancer drug exports. More... (in Chinese) |
| Taiwan's EirGenix Opens Zhubei Plant, Partners with US-based GeneFab 16 September, 2026 EirGenix (TW: 6589) inaugurated its Zhubei microbial commercial production facility on the 16th of September, featuring fermentation capacity ranging from 75 to 1,500 liters. The new plant has already secured commercial production orders for two products from Japanese clients. The company simultaneously signed an agreement with US-based GeneFab to manufacture GMP-grade DNA plasmids, supplying raw materials for therapeutic lentiviral vector production, officially extending its CDMO services into the gene and cell therapy space. More... |
| Pharmosa Biopharm's Inhaled Drug L606 Approved for Global Phase III Pivotal Trial in China 16 September, 2026 Pharmosa Biopharm (TW: 6875) announced on the 16th of September that its partner Liquidia has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trial sites in China for the global Phase III pivotal Re-Spire trial of L606, an inhaled treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Under the licensing agreement, Liquidia will fund and conduct the trial, while Pharmosa Biopharm will manufacture and supply the clinical trial drug. The addition of Chinese sites will expand the global trial network and accelerate patient enrollment. More... (in Chinese) |
| Gongwin Biopharm Invited by UAE for Collaboration, Targeting Middle East Equine Market 16 September, 2026 Gongwin Biopharm (TW: 6617) announced on the 16th of September that it was invited by the Emirates International Endurance Village (EIEV) to present its PTS tumor ablation technology to UAE Vice President Sheikh Mansour bin Zayed Al Nahyan and veterinary experts, opening opportunities in the Middle East's high-value animal healthcare market. Sponsored by Sheikh Mansour, EIEV is a major venue for international endurance horse racing, where equine health, performance, and welfare are priorities. More... (in Chinese) |
| Taiwan Excellence concludes Medical Fair Asia 2026: Bridging healthcare gaps with advanced AI MedTech 15 September, 2026 The Taiwan Excellence Pavilion successfully concluded its participation at Medical Fair Asia 2026 last week at the Sands Expo & Convention Centre, Singapore. Spearheaded by the International Trade Administration (TITA) and the Taiwan External Trade Development Council (TAITRA), the showcase featured 16 premier medtech brands under the banner "From Taiwan with Care - Activate the Future of Wellness". More... |
| TAHO Pharmaceuticals Plans to List in Late October; BEQIA US Approval Expected Next Year 15 September, 2026 TAHO Pharmaceuticals (TW: 6467) recently passed its listing review and plans to list in late October. Its flagship product, BEQIA (TAH3311), an oral dissolving antithrombotic film containing apixaban and designed for patients with swallowing difficulties, has been submitted to the US FDA, with approval expected by the 22nd of April next year if the review proceeds as planned. European approval could come by the end of this year. Apixaban generated US$29.2 billion in US sales in 2025 and ranked among the world's top-selling drugs in 2023 and 2024. More... (in Chinese) |
| APBio Advances Multiple Potential Assets in Parallel 15 September, 2026 At its August investor briefing, APBio's (TW: 6945) strategic partner in China, Innovent Biologics, said it plans to submit a China marketing application for IBI302 to treat neovascular age-related macular degeneration (nAMD) in the fourth quarter. The drug is also being developed for diabetic macular edema (DME), with Phase II data nearing completion, potentially increasing its overseas licensing value. Meanwhile, Phase II trials of AP505 in China have been completed, and APBio plans to apply by year-end for a company-led global Phase II combination-therapy trial. More... (in Chinese) |
| Anxo Pharmaceutical's 505(b)(2) drug Completes World's First Patient Dosing Press release 14 September, 2026 Anxo Pharmaceutical Co. (TW: 6677), a specialized drug delivery technology developer, today (the 14th) announced a major milestone: AX251, its schizophrenia drug candidate that has received FDA clearance for a Phase 1 clinical trial, has completed dosing of the world's first patient, formally launching an international Phase 1 human clinical trial. This marks the moment Anxo's proprietary Nano-Crystal Injectable Platform (NanoCIP) technology officially moves from the laboratory into clinical validation, securing a critical first-mover advantage for the company in the global race for long-acting antipsychotic drugs. More... |
| Three Major Pharmaceutical Companies Chart New Paths, Enter New Growth 14 September, 2026 Some of Taiwan's leading pharmaceutical companies are expected to perform well in the second half of the year, but their growth strategies differ significantly. PharmaEssentia (TW: 6446) is creating a second growth curve by expanding the indications for its novel drug; Bora Pharmaceuticals (TW: 6472) is increasing operational visibility through CDMO orders and capacity expansion via acquisitions; and Lotus Pharmaceutica (TW: 1795) is rapidly expanding its revenue scale through cross-border acquisitions. More... (in Chinese) |
| Mycenax Teams Up with Global Partners to Expedite R&D and Market Launch Next-Generation ADCs 14 September, 2026 As the global number of cancer cases keeps rising and patients are getting younger, high unmet medical needs persist, fueling the development of novel treatment modalities such as antibody-drug conjugates (ADCs). More... |
| Lai touts Taiwan's precision oncology push 13 September, 2026 President Lai Ching-te lauded Taiwan's efforts in cancer research and treatment in a video address marking the 20th anniversary of the Taiwan Society for Molecular Medicine on Sunday. More... |
| Novel drug-releasing electrode protects hearing during cochlear implantation Press release 11 September, 2026 Cochlear implants are life-changing biomedical devices that restore sound perception for individuals with severe to profound hearing loss. However, the surgical insertion of standard electrodes into the delicate inner ear often triggers acute inflammation, tissue scarring and secondary damage to remaining sensory hair cells and auditory neurons. More... |
| 12 CEOs Compete in Startup CEO Awards Event 4 September, 2026 The fourth 2026 Global Bio & Investment Monthly Taiwan Startup CEO Awards were held on the 4th of September, with 12 biomedical startup CEOs competing for the top honors. Jerry Chen, CEO of Brain Navi Biotechnology, won first place, while Patty Sung, general manager of Intelligene, and David Lee, general manager of Singular Wings, took second and third, respectively. More... |
| ========================================= |
| Please note that Taiwan BIO is not responsible for the accuracy of third-party news stories covered in this newsletter. |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2027 (27-31 July, 2027) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |